Waterdrop Inc. (WDH) Earnings
Waterdrop Inc. is expected to report next earnings on September 9, 2026 (in NaN days). WDH has beaten EPS estimates in 4 of its last 7 reported quarters (average surprise +17.6% over the last four).
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Jun 16, 2026 | — | $0.04 | — | $180M | +0.4% |
| Mar 25, 2026 | $0.04 | $0.06 | +55.4% | $202M | +71.4% |
| Dec 3, 2025 | $0.04 | $0.06 | +58.2% | $137M | +13.5% |
| Sep 4, 2025 | $0.19 | $0.06 | -68.4% | $117M | -86.7% |
| Jun 5, 2025 | $0.04 | $0.05 | +25.0% | $104M | -86.4% |
| Mar 25, 2025 | — | $0.02 | — | $94M | — |
| Dec 11, 2024 | $0.03 | $0.06 | +100.0% | $730M | +6.7% |
| Sep 4, 2024 | — | $0.00 | — | $659M | +554.2% |
| Feb 26, 2024 | — | $0.02 | — | $93M | -1.5% |
| Dec 7, 2023 | $0.00 | $0.00 | -23.0% | $94M | -6.8% |
| Jun 2, 2023 | $0.02 | $0.00 | -90.9% | $94M | -14.4% |
| Mar 31, 2023 | — | $0.02 | — | $88M | — |
Source: company filings + earnings calendar. For informational purposes only — not investment advice.
Earnings call summary
Q1 FY2026 · June 16, 2026
AI summary of management’s prepared remarks and analyst Q&A. For informational purposes only — not investment advice.
Management highlights
### Overall Company Performance - The company has maintained profitability for 17 consecutive quarters starting from Q1 2022 - Completed the fifth cash dividend since IPO in early May 2006, totaling ~$10.8 million; as of end of May 2006, $120 million had been used to repurchase ~61.8 million ADRs, with total cumulative capital return (dividends + repurchases) reaching ~$170 million since IPO - The Water Drop Charity Platform had partnered with 119 public charitable organizations and launched over 15,500 charity programs as of Q1 end ### Technology and AI Development - Accelerating the transition to an AI-native company: as of March 31 2006, 75 LLM-related patent applications had been filed (9 international), with 2 new national innovation patents granted for intelligent semantic understanding and multimodal recognition - AI technology is being progressively deployed across insurance customer service and claims processes to improve service quality and efficiency - The Waterboxx Digital AI low-cost AI platform now provides over 30 purpose-built scenario-specific agents for internal teams and external clients ### Insurance Business Operations - Continued aggressive public domain user acquisition and increased investment in traffic and AI to drive premium growth; proactively cut lower ROI channels and expanded high-quality alternative channels, leading to improved overall ROI - FYP for pre-existing condition products grew 24.3% year-over-year, and disability insurance FYP reached $89 million in the quarter; product iteration expanded coverage: inclusive cancer insurance upgraded to cover out-of-hospital prescriptions, medical devices and advanced cancer services, and a new simplified-underwriting cancer-specific product was launched to lower the barrier for lifelong cancer protection - Multiple after-sales service improvements: dedicated complaint hotline, connected payment and customer service systems for faster refunds, simplified procedures and fast-track service for elderly customers accessing support via their children - AI tools streamlined workflows: user-facing AI applications drove 87 million yen in incremental premiums (up 17.7% sequentially); AI underwriting tools have handled over 10,000 underwriting inquiries to date; internal beta testing of a cloud co-pilot for CRM and WeCom began in late March to reduce system switching for sales teams and support sales review and performance analytics; AI customer service agents handle over 1 million monthly service interactions, delivering over twice the efficiency of manual-only service ### Medical Crowdfunding and Digital Healthcare Operations - Medical crowdfunding: Completed a quarterly AI-assisted risk review upgrade that speeds up preliminary screening while maintaining risk control quality; added minority language specialists and dedicated end-to-end tracking teams to improve service for linguistically diverse regions, reducing communication barriers while maintaining compliance and cultural sensitivity - Digital clinical trial solutions: Q1 patient enrollment grew 16% year-over-year, new signed products increased 53% year-over-year; 128 new trial programs were initiated in partnership with 243 biopharmaceutical companies; cumulative enrollment exceeded 15,500 patients as of Q1 end - Secured a national invention patent for intelligent drug-patient matching technology (the first of its kind in China) in January 2006; built a standardized end-to-end pipeline from data structuring to intelligent patient-trial matching, and expanded the medical case library for complex indications to support long-term sustainable growth
Guidance
- Management has set growth as the company's top priority for full-year 2006, and plans to further increase marketing investment based on proven user targeting capabilities - Management guides full-year 2006 top-line revenue growth of approximately 40% - Operating profit margin is expected to remain stable in 2006, as current investments are intended to unlock larger profit potential in future years - Expanded user base is expected to further support the company's long-term development
Segment performance
Total company revenue for Q1 2006 was $1.24 billion, representing 64.8% year-over-year growth. 1. Insurance Business: Insurance-related revenue reached $1.15 billion, up 74.1% year-over-year, accounting for approximately 92.2% of total revenue. It generated $115 million in operating profit, with a 13.3% operating margin, and operating margin increased 2 percentage points quarter-over-quarter. 2. Medical Crowdfunding (Profunding) Segment: Generated approximately $16.73 million in revenue, contributing ~1.3% of total revenue. As of quarter end, the platform had cumulatively raised 73.5 billion yuan for 3.75 million patients across 494 million cumulative donors. 3. Digital Healthcare/Clinical Trial Solutions Segment: Generated approximately $24.2 million in revenue, contributing ~1.9% of total revenue. Combined non-insurance segments accounted for 7.8% of total revenue. Overall company operating profit for Q1 was approximately $79.95 million, with a 5.3% operating margin, and net profit attributable to ordinary shareholders was $98.4 million, down 9.1% year-over-year.
Risks & headwinds
Management noted that forward-looking statements are inherently subject to risks and uncertainties that could cause actual results to differ materially from current expectations. Potential risks include those outlined in the company's public filings with the U.S. SEC. No additional specific operational or financial risks were discussed in the prepared remarks portion of the call.